Section Arrow
Quote
RARE.NASDAQ
- Ultragenyx Pharmaceutical
Quotes are at least 15-min delayed:2026/06/03 17:51 EDT
After Hours
Last
 22.41
0 (0.00%)
Bid
21
Ask
23.25
High 22.41 
Low 22.41 
Volume 29.41K 
Regular Hours (Closed)
Last
 22.41
+0.63 (+2.89%)
Day High 
22.605 
Prev. Close
21.78 
1-M High
27.42 
Volume 
1.80M 
Bid
21
Ask
23.25
Day Low
21.805 
Open
21.85 
1-M Low
21.33 
Market Cap 
2.15B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 23.13 
20-SMA 24.45 
50-SMA 23.59 
52-W High 42.37 
52-W Low 18.29 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-6.10/1.10
Enterprise Value
2.17B
Balance Sheet
Book Value Per Share
-2.40
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
673.00M
Operating Revenue Per Share
4.16
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc.0.0949-0.0149-13.57%-- 
After Hours 0.0889 -0.006 -6.32%
VRAXVirax Biolabs Group Limited0.2401+0.0238+11.00%-- 
After Hours 0.2071 -0.033 -13.74%
RXRXRecursion Pharmaceuticals3.47-0.14-3.88%-- 
After Hours 3.44 -0.03 -0.86%
CLDICalidi Biotherapeutics0.1656-0.0145-8.05%-- 
After Hours 0.1663 +0.0007 +0.42%
GOSSGossamer Bio0.1883-0.0119-5.94%-- 
After Hours 0.1882 -0.0001 -0.05%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitatinggenetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated fromNorth America.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.